ProAffin Raises €14.1 Million
ProtAffin AG, an Austrian developer of drugs that target cell-surface glycan structures, has raised €14.1 million in Series B funding. Atlas Venture and S.R. One Ltd. co-led the round, and were joined by return backers Aescap Venture, Entrepreneurs Fund and Z-Cube.
27 April 2009•4 mins read
